NCT Number: NCT00357383
Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers
To evaluate the ocular tolerance of T1225 1% and 1.5% eye drops versus vehicle after one instillation twice-daily (morning and evening), in one eye, during 3 days (from Day 0 to Day 2).
To assess azithromycin tear, conjunctiva and plasmatic concentrations, after a 3-day treatment period
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
About this study
The aim of the present study was to compare ocular tolerance and safety after repeated instillations of T1225 1% and 1.5% eye drops and vehicle and to assess the residual azithromycin concentrations in tear, ocular conjunctiva and plasma samples, approximately 12 hours after the last Investigational Medicinal Product instillation.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female aged from 18 to 45 years old;
- Written informed consent;
- Healthy volunteers without any subjective ocular symptom;
- Normal ocular examination in both eyes (corrected visual acuity >= 6/10, normal slit lamp examination, tear prism height > 0.1mm, tear break-up time (BUT) >= 10 seconds, lissamine green test score < 4);
- Registered, or agreed to be registered, in the national register of healthy volunteers
Exclusion criteria
- Ocular trauma, infection or inflammation within the last 3 months;
- number of corneal stained punctuations Ocular trauma, infection or inflammation within the last 3 months;
- number of corneal stained punctuations >= 5;
- blepharitis, conjunctivitis, uveitis;
- contact lenses;
- topical ocular treatment within the last month;
- ocular laser within the last 3 months;
- ocular surgery, including LASIK and PRK, within the last 12 months;
- systemic macrolide within the last month;
- medication during the study (except: paracetamol and contraceptives).
Treatment and study plan
Primary outcomes
-
Ocular pharmacokinetic in tears
Secondary outcomes
-
Tolerance
Sponsors and collaborators
Lead sponsor
Laboratoires Thea
Industry
Registry information
Important dates
- Study start
- 2002
- Study completion
- 2002
- First posted
- Jul 27, 2006
- Registry last updated
- Jul 27, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Steroids for Corneal Ulcers Trial
NCT00324168
Bacterial Infections, Bacterial Infections and Mycoses
San Francisco, California, United States
View Trial DetailsOcular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers
NCT00357292
Bacterial Infections, Bacterial Infections and Mycoses
View Trial DetailsSafety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers
NCT00357539
Bacterial Infections, Bacterial Infections and Mycoses
Clermont-Ferrand, France
View Trial DetailsOcular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers
NCT00356850
Bacterial Infections, Bacterial Infections and Mycoses
View Trial Details